However, there was no significant change observed on the expression of these molecules in non-MYCN amplified neuroblastoma cells, suggesting combination specificity to MYCN-amplified neuroblastoma cells targeting NF-kB and mTOR pathways. The gene discussed is MYCN; the disease is neuroblastoma.